.png){kind=icon}
.png){kind=icon}
Return
MβCD@HA-Ad nanoparticles inhibit pancreatic cancer progression by targeting Caveolin-1/Piezo1/PLA2G4A-mediated lipid reprogramming
.png){kind=icon}
PRE
AI
Y
X
X
Y
Y
Z
Y
Y
D
DOI：10.1016/j.jconrel.2026.115223.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Caveolin-1 represents a potential therapeutic target for pancreatic cancer, and methyl-β-cyclodextrin (MβCD)—a cholesterol-depleting agent that indirectly disrupts Caveolin-1 function via caveolae destabilization—holds therapeutic potential for pancreatic cancer treatment. • A supramolecular nanoassembly (MβCD@HA-Ad) was developed to integrate active targeting, acid-responsive release, and colloidal stability into a single platform. The system enables CD44-mediated tumor localization and Caveolin-1-directed functional inhibition, with drug release triggered by the acidic tumor microenvironment. • Caveolin-1 drives pancreatic cancer proliferation and metastasis through lipid metabolism reprogramming and mechanical stress sensing, revealing the Piezo1/PLA2G4A axis as a key regulatory pathway. • This study establishes a precision strategy targeting the Caveolin-1/Piezo1/PLA2G4A axis, offering a translational therapeutic approach for pancreatic cancer and potentially other solid tumors.
Journal
IF:
11.5
Papers:
1.5W
Citations:
7.4W
Organization
Cited Papers